Results from the Breast Screening - Risk Adapted Imaging for Density (BRAID) study were recently published in The Lancet. BRAID is "the first randomized controlled trial to compare supplemental imaging of abbreviated magnetic resonance imaging (MRI), automated who breast ultrasound (ABUS), and contrast-enhanced mammography with standard mammography (standard-of-care) in women of average population risk with dense breasts and a negative screening mammogram."
For a period of 4.5 years (October 2019 - March 2024), 9361 women aged 50-70 across the UK were recruited and randomly assigned to ether abbreviated MRI, ABUS, or contrast-enhanced mammography. Per 1000 examinations, cancer detection rate was 17.4 for abbreviated MRI, 4.2 for ABUS, and 19.2 for contrast-enhanced mammography.
Click here to read more about the BRAID trial.
Sources mentioned:
- Gilbert FJ, Payne N, Allajbeu I, et al. Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial . The Lancet; Published online 21 May 2025. DOI: 10.1016/S0140-6736(25)00582-3
- Houssami N. Breast cancer screening at a crossroads: supplemental imaging for dense breasts . The Lancet; Published online 21 May 2025. DOI: 10.1016/S0140-6736(25)00803-7